"In the Spotlight: LinXis technology discussed in Dutch medical oncology journal"Read more
The LinXis management team members have extensive experience in the biotechnology field, with specializations in medicine, drug development, intellectual property and business development.
Scientific Advisory Board
The LinXis Scientific Advisory Board consists of experts and industry veterans, who all strongly believe in LinXis and its platform technology.
Executive board, Chief Executive Officer
Paul Steverink (1962; DVM, PhD) is responsible for overall corporate strategy. He holds a PhD in immunology and headed the vaccine development group for endemic diseases, and the IP and licensing department, at ID Lelystad. In addition he has an MBA from Erasmus University, Rotterdam, with a focus on corporate finance. He has taken the lead in (financially) structuring several international commercial transactions, in particular transactions with significant intellectual property components. Paul has been and is CFO of a variety of biotech companies.
Executive board, Chief Operating Officer
Bart Nijmeijer (1972; PhD) is responsible for operational activities since April 2018. Bart obtained his PhD at the Leiden University Medical Center, on immunotherapy of hematological malignancies. Former to his position at LinXis, Bart led the Analytical Development department of a Dutch mid-sized gene therapy company (2010-2018), where he also acted as the manufacturing lead in the company’s main alliance.
He was actively involved in the development of a gene therapy product for for Hemophilia B, from preclinical phase up to clinical phase II/III. He has hands-on experience in manufacturing and QC activities, preclinical safety/toxicology assessment, bio-analytical development and regulatory interactions.
Executive board, Chief Financial Officer
Samuel Oudkerk (1981; Business Studies) is responsible for LinXis’ finances and business development. Samuel started his career at Deloitte, where he focused on CFO-Services, developing new business models for venture capital in Lifesciences. Former to his position at LinXis, Samuel was partner at Surmount Ventures, a niche private equity company focused on impact investing, where he was responsible for improvements to portfolio operations in the Life Sciences- and Agricultural industry. He has more than 10 years of experience in transactions, and building start-ups and scale-ups. Inspired by developments in impact investment field, Samuel will use his knowledge and industry expertise to help bring LinXis to the next stage.
Non-executive board, Scientific Director
HendrikJan Houthoff (1943; MD, PhD, Prof emeritus) is founder of LinXis. He devotes his time to the company’s scientific strategy. He was full professor in human pathology at several Dutch universities (1970-1989) and founder, CEO and CSO of Kreatech Biotechnology (1990-2003). Under his supervision, Kreatech started in 2002 with European research projects in the development of targeted drugs for the treatment of liver cirrhosis and kidney fibrosis. With LinXis HendrikJan continues the research on drug targeting technologies.
Gerro van Rheenen (1956; MD) has been a valuable part of the LinXis management team since 2014 and devotes his time to marketing and sales management.
He started his career as a general practitioner with a profound interest in Medical Sciences. He has an entrepreneurial, marketing and sales background in medical and customer care products and was founder and CEO of several customer care companies. He combines analytical and creative thinking with a cooperative character that enables him to mediate LinXis’ partnering and networking activities.
Guus van Dongen (1956; PhD, Prof) is an invaluable advisor to LinXis with his scientific and medical expertise in imaging and antibody development. He advises and steers the LinXis research team on a daily and stand-by basis.
As a professor at the VUmc Department of Radiology & Nuclear Medicine, Tracer Center Amsterdam, and project leader of the VU University Medical Imaging Center, Amsterdam, he has become an international expert in preclinical and clinical molecular imaging, in the development of monoclonal antibodies (mAbs) and antibody conjugates like ADCs, and in the in the image-guided (pre)clinical evaluation of new targeted drugs. His department serves many leading biotech, pharma and imaging companies, as well as innovative start-ups, and has brought > 25 antibody conjugates, prepared in own licensed GMP facilities, in first-in-human studies. He is (co)author of close to 200 peer-reviewed papers, holds an h-index of 54, and is inventor at several patents.
Jan Reedijk is professor emeritus at the Leiden Institute Chemistry, of Leiden University. He is a highly renowned international expert in platinum chemistry, metal coordination by ligands and metal applications in medicine. He has well over 1200 (co-)authored refereed research publications and patents (1965 - 2015). During his academic career he has supervised over 250 MSc student projects, over 90 postdocs and 90 graduate students (1973-2011). His h-index (WoS spring 2015) is listed as 85. He has served or is still serving in over 15 editorial boards of scientific journals.
A selection of major honors includes: (1) Awarded of the Max Planck Research Award in Chemistry (1992). (2) Elected Member of the Royal Netherlands Academy of Sciences (1996), (3) Elected Member Finnish Academy of Sciences (1997); (4) Elected Member of the Academia Europaea (2003); (5) Honorary fellow of the Royal Netherlands Chemical Society (2003); (6) Royal Knighthood to the order of the Dutch Lion (2008).
H.M. Bob Pinedo, MD, PhD, is professor emeritus of Medical Oncology at the VU University Medical Center (VUmc). He was the founder of the VUmc Cancer Center Amsterdam (CCA) and is advisor to the CCA Board. He served 25 years as chief of the VUmc Department of Oncology and still practices medical oncology.
Dr. Pinedo’s honors are many including the prestigious Dr. Josef Steiner Cancer Research Foundation Award (1995), The Netherland’s Spinoza Prize (1997) and recently the David A. Karnofsky Memorial Award of the American Society of Clinical Oncology (2014). He has received the Knight of the Order of the Netherlands Lion and Commander in the Order of Orange Nassau from Queen Beatrix of the Netherlands. In his honor the annual Pinedo Award for clinical patient care was established in 2006 by the Society of Translational Oncology. He is a member of the Royal Dutch Academy of Science as well as visiting professor at the Johns Hopkins University and the Technical University of Twente, Netherlands. His curriculum vitae includes more than 300 invited lectures, multiple service on boards and committees of numerous European and American organizations, and more than 600 publications as author or coauthor in peer reviewed international journals. He is co-founder of the Center for Translational Molecular Medicine in the Netherlands. He was the first President of the Federation of European Cancer Societies (FECS), the first President and co-founder of European Cancer Organization (ECCO), and Past President to the European Society of Medical Oncology (ESMO). He is past member of the EORTC Board and the ASCO Science Committee. He is Chairman of the International Advisory Committee of the Imaging Center to be established at the VU medical center in Amsterdam with the aim to facilitate targeting agents and personalized medicine for cancer patients in the Netherlands and internationally. Translational cancer research and care for cancer patients are of fundamental importance to Prof. Pinedo.
Professor Yvette van Kooyk chairs the division Dendritic Cell Biology at the VU University Medical Center in Amsterdam. She obtained her PhD cum laude in 1993 at the Medical Faculty of the University of Amsterdam, on her work performed at the Netherlands Cancer Institute, revealing pioneering molecular mechanisms that regulate immune cell adhesion through integrin activation.
In 2001, she discovered the, innate receptor DC-SIGN a C-type lectin on Dendritic cells, playing a crucial role in HIV recognition and cellular interactions through the recognition of glycan structures. This discovery set the stage of a whole new field that led to new concepts on pathogen interactions through C-type lectin receptor, that modify Dendritic cell responses.
Through a Pionier grant she directed her research line into the field of functional glycomics, a field neglected by immunologist, which focuses on the understanding how the exposed glycans on glycoproteins/lipids, are instrumental for the functional activity of proteins, and in cellular communication. She pioneered this field successfully leading to new scientific discoveries, but also to clinical applications into the field of DC-targeting strategies, improving/inhibiting immune responses, and in the field of diagnostics by constructing glycan detection probes for new discovery of tumor associated diseases, linking basic science driven research to translational research. She received ERC-Advanced in 2013 for this research line.
Because her research focus is on conceptual questions that relate to defining DC modifying strategies, her work covers the field of cancer, auto immunity and infectious diseases.
Her current research program comprises 1. “Modulation of immuneresponses by glycans’’ and 2.”DC targeting to improve anti-cancer responses”. She has (co-)authored 220 peer-reviewed publications in international scientific journals and 13 book chapters. Professor van Kooyk has supervised 28 PhD students (1992-2015) of which 2 cum laude and 15 postdoc of which 1 recently became professor. Her current teaching activities involve the coordination of a Bachelor course in Immunology for Biomedical Sciences and Health Sciences and the Research Master Immunology. She received various prestigious grants such as PIONIER and the ERC-Advanced and the van Loghem prize. She is active member of several scientific committees, e.g. board member of the Dutch Society for Immunology, Dutch Cancer Foundation, Board member Cancer Center Amsterdam(CCA) . Finally, she is inventor on 4 patents and is Chief Scientific Officer of the start-up biotech company DC4U
Paul van Bergen en Henegouwen (1955; PhD) studied biology at the University of Amsterdam and received his PhD in 1986 at the Utrecht University. After several years of postdoctoral research, he joined in 1995 the Cell Biology group at the Science Faculty of the Utrecht University, where he is currently an associate professor and principal investigator. He is specialized in cell biology, molecular imaging and targeted therapy. A common theme in his research are the receptors from the ErbB2 family (EGFR, HER2/neu). He has developed various targeting molecules against these receptors, which he uses to study the behavior of ErbB receptors in the cell using X-ray crystallography, solid state NMR and super-resolution light microscopy. He is (co)author of >120 peer-reviewed papers, h-index 44, and is inventor at >16 patents.